CNS PHARMACEUTICALS INC(NASDAQ:CNSP) stock News

CNSP Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: BLRX PRQR SXTC BCAB ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a month ago - By: Benzinga - Mentions: HBIO TTNP ADAP ABEO ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

2 months ago - By: ACCESS Newswire

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: ACCESS Newswire

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

3 months ago - By: ACCESS Newswire

CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

5 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

3 months ago - By: ACCESS Newswire - Mentions: AKTX AMIX NVNO GRI ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

3 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Announces Reverse Stock Split

3 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

7 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

4 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

5 months ago - By: ACCESS Newswire

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

5 months ago - By: Stocktwits - Mentions: VXF

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

8 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

5 months ago - By: ACCESS Newswire

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

7 months ago - By: ACCESS Newswire

CNS PHARMACEUTICALS INC (CNSP) Stock News

CNSP Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme